MorphoSys AG
MorphoSys AG
- Market cap
- $11.41B
Your view on MOR
Overview
What the company does, where it operates, and who runs it.
About MorphoSys AG
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Arkadius Pichota
- Headquarters
- DE
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Arkadius Pichota
- Headquarters
- DE
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States.
It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2.
In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases.
MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma.
The company was founded in 1992 and is headquartered in Planegg, Germany.
Past Reports
Historical coverage archive.
*MorphoSys AG had paid FRC a fee for research coverage and distribution of reports. This fee creates a potential conflict of interest which readers should consider.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for MorphoSys AG. Starting points for MorphoSys AG: EPS -$1.38, beta 0.66 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for MorphoSys AG. Trailing twelve-month EPS for MorphoSys AG stands at -$1.38. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Analyst Ratings
- Strong Buy0
- Buy5
- Hold5
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrJun 2024 | Next QtrSep 2024 | Current YearFY Dec 2024 | Next YearFY Dec 2025 |
|---|---|---|---|---|
| Avg. estimate | EUR 0.00 | −EUR 0.56 | −EUR 2.38 | −EUR 1.37 |
| Low estimate | EUR 0.00 | −EUR 0.56 | −EUR 2.69 | −EUR 2.14 |
| High estimate | EUR 0.00 | −EUR 0.56 | −EUR 1.88 | −EUR 0.58 |
| No. of analysts | 0 | 1 | 4 | 3 |
| Year-ago EPS | −EUR 0.541 | −EUR 0.871 | −EUR 1.381 | — |
| Growth | — | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrJun 2024 | Next QtrSep 2024 | Current YearFY Dec 2024 | Next YearFY Dec 2025 |
|---|---|---|---|---|
| Avg. estimate | EUR 29.05M | EUR 50.29M | EUR 220.26M | EUR 324.17M |
| Low estimate | EUR 29.05M | EUR 50.29M | EUR 173.12M | EUR 317.28M |
| High estimate | EUR 29.05M | EUR 50.29M | EUR 267.41M | EUR 331.05M |
| No. of analysts | 1 | 1 | 2 | 3 |
| Year-ago revenue | EUR 53.17M | EUR 63.80M | EUR 238.28M | — |
| Growth | −45.4% | −21.2% | −7.6% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for MorphoSys AG. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| JBIOJade Biosciences, Inc. | Healthcare | NASDAQ | $1.1B | ||
| JSPRJasper Therapeutics, Inc. | Healthcare | NASDAQ | $12.8M | ||
| JSPRWJasper Therapeutics, Inc. | Healthcare | NASDAQ | $3,251 | ||
| JUNSJupiter Neurosciences, Inc. | Healthcare | NASDAQ | $2.0M | ||
| JWCTFJW (Cayman) Therapeutics Co. Ltd | Healthcare | OTC | $127.5M | ||
| KALAKALA BIO, Inc. | Healthcare | NASDAQ | $2.1M | ||
| KAPAKairos Pharma, Ltd. | Healthcare | AMEX | $1.5M | ||
| KARDKardigan, Inc. | Healthcare | NASDAQ | $1.1B | ||
| KLDOKaleido Biosciences, Inc. | Healthcare | OTC | $4,262 | ||
| KLRAKailera Therapeutics, Inc. | Healthcare | NASDAQ | $1.5B | ||
| KLRSKalaris Therapeutics Inc | Healthcare | NASDAQ | $32.6M | ||
| KNBIFKane Biotech Inc. | Healthcare | OTC | $4.6M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for MorphoSys AG. Coverage tracks MorphoSys AG within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of MorphoSys AG.